These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

165 related items for PubMed ID: 4342755

  • 1. [Evaluation of fluphenazine use since establishment of a psychiatric section].
    Roger BM.
    Ann Med Psychol (Paris); 1972 Apr; 1(4):550-5. PubMed ID: 4342755
    [No Abstract] [Full Text] [Related]

  • 2. [Comparative study of delayed-action neuroleptics in psychiatric therapeutics].
    Pellet J, Guyotat J, Marie-Cardine M, Dubor P, Favre-Tissot M, Caron F, Cottraux J.
    J Med Lyon; 1972 Apr 20; 53(227):591-8. PubMed ID: 4404295
    [No Abstract] [Full Text] [Related]

  • 3. [Trial at the guidance center of ixelles of a major neuroleptic drug: anatensol decanoate].
    Berliner J.
    Acta Psychiatr Belg; 1974 May 20; 74(3):305-16. PubMed ID: 4455024
    [No Abstract] [Full Text] [Related]

  • 4. Fluphenazine decanoate vs oral antipsychotics: a comparison of their effectiveness in the treatment of schizophrenia as measured by a reduction in hospital readmissions.
    Devito RA, Brink L, Sloan C, Jolliff F.
    J Clin Psychiatry; 1978 Jan 20; 39(1):26-34. PubMed ID: 24614
    [Abstract] [Full Text] [Related]

  • 5. [Results of therapy with Lyogen-Depot in schizophrenic diseases].
    Friemert K, Beier R, Vehreschild T.
    Psychiatr Neurol Med Psychol (Leipz); 1974 Jun 20; 26(6):374-7. PubMed ID: 4849639
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Discontinuation of oral and depot fluphenazine in schizophrenic patients after one year of continuous medication: a controlled study.
    Levine J, Schooler NR, Severe J, Escobar J, Gelenberg A, Mandel M, Sovner R, Steinbook R.
    Adv Biochem Psychopharmacol; 1980 Jun 20; 24():483-93. PubMed ID: 6996445
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Characteristics of the therapeutic action fluphenzaine decanoate (moditen-depot) in schizophrenia].
    Tsutsul'kovskaia MIa, Minsker EI, Panteleeva GP, Mazurskii MB, Pekunova LG.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1973 Jun 20; 73(5):753-8. PubMed ID: 4718619
    [No Abstract] [Full Text] [Related]

  • 11. [Effects of long-acting fluphenazine].
    Marcjan K, Pietruszewska I, Wolak E.
    Psychiatr Pol; 1973 Jun 20; 7(1):79-86. PubMed ID: 4715837
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Outpatient management of chronic schizophrenics with fluphenazine enanthate (Prolixin enanthate): a clinical evaluation.
    Carder SL, Snibbe J.
    Curr Ther Res Clin Exp; 1973 Sep 20; 15(9):589-98. PubMed ID: 4356319
    [No Abstract] [Full Text] [Related]

  • 18. [Clinical observation on the effect of domestic fluphenazine decanoate in the treatment of schizophrenia---report of 431 cases (author's transl)].
    Zhang YF.
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1981 Aug 20; 14(3):182-5. PubMed ID: 7333179
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.